Drugs / AVT03
AVT03
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05876949 | Jul 2023 → Apr 2024 | — | Alvotech Swiss AG | Completed | No outcome recorded |
| Phase 1 | NCT05126784 | Jun 2022 → Oct 2023 | — | Alvotech Swiss AG | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05395091 | Aug 2022 → May 2024 | postmenopausal osteoporosis | Alvotech Swiss AG | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVT03 | “AVT03 (denosumab) is a recombinant fully human IgG2 monoclonal antibody to RANKL to be administered as a subcutaneous injection.” NCT05395091 ↗ |
| Known as | AVT03, Biosimilar Denosumab | “AVT03, Biosimilar Denosumab” NCT05126784 ↗ |
| Known as | denosumab | “AVT03 (denosumab) is a recombinant fully human IgG2 monoclonal antibody to RANKL to be administered as a subcutaneous injection.” NCT05395091 ↗ |
| Route | Subcutaneous | “will be given as single subcutaneous injection” NCT05126784 ↗ |